Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

NCT06508463 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06508463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06508463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
January 5, 2024
Completion date
April 1, 2032
Enrollment
21 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, mycosis fungoides, peripheral t cell lymphoma, peripheral t-cell lymphoma, not otherwise specified, relapsed anaplastic large cell lymphoma, relapsed mycosis fungoides, relapsed peripheral t-cell lymphoma